Uncommon EGFR G724S mutations arise in non-small-cell lung cancer patients with acquired resistance to first-generation EGFR-TKIs

Lung Cancer. 2018 Apr:118:173-175. doi: 10.1016/j.lungcan.2018.02.016. Epub 2018 Mar 2.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acrylamides
  • Aniline Compounds
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Drug Resistance, Neoplasm / genetics
  • ErbB Receptors / genetics
  • Erlotinib Hydrochloride / therapeutic use
  • Gefitinib / therapeutic use
  • Genetic Testing
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics*
  • Mutation / genetics*
  • Piperazines / therapeutic use
  • Protein Kinase Inhibitors / therapeutic use
  • Treatment Outcome

Substances

  • Acrylamides
  • Aniline Compounds
  • Antineoplastic Agents
  • Piperazines
  • Protein Kinase Inhibitors
  • osimertinib
  • Erlotinib Hydrochloride
  • EGFR protein, human
  • ErbB Receptors
  • Gefitinib